What happened to Peptide Sciences
Peptide Sciences, the largest research peptide vendor in the United States by web traffic, voluntarily shut down operations on March 6, 2026. The closure came without advance warning. The company's website now displays only a brief shutdown notice.
At the time of closure, Peptide Sciences was generating an estimated $7.4 million per month in revenue and receiving approximately 990,000 monthly visits according to third-party analytics. The company had operated for over a decade, building a catalog of more than 190 research compounds spanning growth hormone secretagogues, metabolic peptides, tissue repair factors, cognitive research compounds, and longevity-related peptides.
The abrupt nature of the shutdown caught the research community off guard. No public statement was issued explaining the decision. Ongoing orders were reportedly canceled, and customer service channels went dark within days. Researchers reported receiving no email notification, no timeline for order fulfillment, and no guidance on refund procedures. Social media and research forums saw an immediate spike in posts from investigators attempting to contact the company through every available channel.
For researchers who had relied on Peptide Sciences as their primary supplier — many for years — the closure created an immediate supply chain disruption. Academic laboratories with grant-funded projects on fixed timelines were particularly affected, as qualifying a new vendor and validating compound equivalence can take weeks or months.
The timing of the shutdown, coming amid an unprecedented wave of regulatory enforcement against peptide vendors, has led many industry observers to conclude that Peptide Sciences chose to close proactively rather than face potential enforcement action.
Why Peptide Sciences shut down
The closure did not happen in a vacuum. It followed a sustained escalation of federal enforcement activity targeting the research peptide and compounding pharmacy industries throughout 2025 and into early 2026.
FDA enforcement escalation. Beginning in September 2025, the FDA issued more than 50 warning letters to peptide vendors, compounding pharmacies, and related businesses, citing violations ranging from unapproved drug distribution to misbranding and manufacturing deficiencies. The pace and volume of enforcement was unprecedented for the peptide sector. Each warning letter carried the implicit threat of injunctions, seizures, and criminal referrals for non-compliance.
The Amino Asylum warehouse raid. In June 2025, federal agents raided the warehouse operations of Amino Asylum, another prominent research peptide vendor. The raid signaled a shift from warning letters to direct physical enforcement. For vendors across the industry, the raid demonstrated that the FDA was willing to deploy its most aggressive tools. This event is widely viewed as a turning point that prompted several vendors to reevaluate their risk exposure.
Resolution of the semaglutide shortage. In February 2025, the FDA officially resolved the semaglutide drug shortage. This resolution eliminated the legal loophole that had allowed compounding pharmacies — and by extension, some research peptide vendors — to produce and sell semaglutide analogs and GLP-1 compounds under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. With the shortage resolved, continued sale of these compounds became significantly riskier. Given the enormous revenue that GLP-1-related compounds generated for vendors, the loss of this market segment likely factored into financial calculations.
The SAFE Drugs Act. Introduced in early 2026, the Strengthening and Advancing Federal Enforcement of Drugs Act proposed expanded authority for the FDA to pursue enforcement actions against entities distributing unapproved peptide products. While the legislation had not yet passed at the time of Peptide Sciences' closure, its introduction signaled bipartisan Congressional support for tighter regulation of the peptide market.
Quality failures and third-party testing. Independent analyses published by Finnrick Analytics exposed quality concerns across multiple vendors, including Peptide Sciences. Reports documented retatrutide counterfeits circulating in the market and poor purity scores for CJC-1295 from several suppliers. These findings undermined the quality assurances that vendors had marketed to researchers and created additional reputational and legal exposure.
Taken together, these factors created what many industry analysts describe as an untenable operating environment. Rather than wait for a warning letter, inspection, or raid, Peptide Sciences appears to have made the calculation that voluntary closure was preferable to the alternatives.
What this means for the research peptide market
The closure of Peptide Sciences removed the single largest vendor from the market virtually overnight. The approximately 990,000 monthly visits represent a substantial population of researchers, academic institutions, and independent investigators who now need alternative suppliers. The downstream effects are reshaping the market in several ways.
Immediate supply disruption. Researchers with active projects faced abrupt supply chain failures. Those in the middle of longitudinal studies or multi-phase research protocols were forced to either pause their work or rapidly qualify new suppliers. Switching vendors mid-study introduces variables around compound purity, synthesis methodology, and batch consistency that can compromise data integrity.
Heightened quality scrutiny. Ironically, the closure has intensified scrutiny of supplier quality rather than diminishing it. The third-party testing data that contributed to Peptide Sciences' risk calculus is now being applied more broadly. Researchers are asking harder questions about purity verification, analytical methodology, and whether certificates of analysis represent genuine independent testing.
Regulatory momentum. The regulatory environment continues to tighten. RFK Jr. has publicly announced plans for peptide reclassification that could fundamentally alter how research compounds are categorized, sold, and regulated. The direction of travel is clear: the era of minimal oversight for research peptide vendors is ending.
Market consolidation. With the largest vendor gone, the remaining players are absorbing displaced demand. This creates both opportunity and risk. Vendors without adequate quality systems or compliance practices may struggle under increased volume. Those with robust operations and documented quality standards are positioned to serve researchers who now prioritize reliability and analytical verification over brand familiarity.
The underlying demand for high-purity research compounds from academic institutions, independent researchers, and scientific organizations remains strong. What is changing is the standard of quality, transparency, and compliance that researchers expect from their suppliers.
What researchers should look for in a peptide supplier in 2026
In the post-Peptide Sciences landscape, researchers evaluating alternative suppliers should apply rigorous criteria before placing orders.
Third-party Certificate of Analysis with every order. A legitimate COA should accompany every batch, not be available only upon request. The COA must be batch-specific — generic COAs reused across batches are a red flag. Review the COA for specific batch numbers, testing dates, analyst information, and testing laboratory identification. For a detailed guide on evaluating analytical documentation, see How to Read a Certificate of Analysis.
HPLC verification and mass spectrometry. HPLC remains the gold standard for purity quantification; mass spectrometry provides identity confirmation. Suppliers should provide both for every compound. Request the actual chromatogram images, not just numerical purity percentages. A deeper discussion of these methods is available in the article on Peptide Purity.
Endotoxin testing. Bacterial endotoxin contamination is a critical quality parameter for research compounds used in cell culture and in vitro assays. Limulus Amebocyte Lysate (LAL) testing or recombinant Factor C assays detect endotoxin contamination. Suppliers who skip this step are cutting corners on fundamental quality assurance.
Cold-chain shipping. A compound that leaves the warehouse at 99% purity can arrive significantly degraded if shipped without thermal protection, particularly during summer months or to warmer climates. Suppliers should ship with insulated packaging and cold packs as standard practice, not as a premium add-on.
Transparent purity data. Research-grade compounds should meet a minimum purity threshold of 98%, with demanding research applications requiring 99% or higher. Suppliers should publish their purity standards and provide compound-specific analytical data rather than blanket marketing claims.
US-based operations. Domestic operations provide accountability, faster shipping, and clearer regulatory jurisdiction. They also face direct FDA oversight, which — while a constraint — provides a layer of quality assurance.
These criteria represent the baseline for responsible research compound sourcing in an era where the consequences of quality failures extend beyond wasted experiments.
How Black Series Lab is different
Black Series Lab was designed to meet the quality and transparency standards that the research community increasingly demands. All compounds are intended solely for research purposes.
Black Series Lab maintains a curated catalog of research-grade compounds, each held to a minimum purity standard of ≥99% as verified by independent third-party analytical testing. Every order ships with a batch-specific Certificate of Analysis documenting HPLC purity quantification and mass spectrometry identity confirmation — not optional documentation, but standard practice with every shipment.
Endotoxin testing is performed on all compounds. All shipments are cold-chain packaged as standard, not as an upgrade. Insulated containers with temperature-maintaining materials protect compound integrity from warehouse to laboratory. A 99% pure compound that arrives degraded due to heat exposure during transit is no longer a 99% pure compound.
Black Series Lab operates entirely within the United States, with domestic warehousing, customer service, and quality oversight. Researchers can browse the full catalog to review available compounds, pricing, and category organization.
The approach is straightforward: independently verified, high-purity research compounds with complete analytical documentation and proper handling at every step of the supply chain. In a market where trust has been eroded by quality failures and abrupt closures, the response is not marketing — it is documentation.
What products did Peptide Sciences carry
Peptide Sciences maintained one of the largest research peptide catalogs in the industry — over 190 SKUs spanning growth hormone secretagogues, metabolic research peptides, tissue repair and healing factors, cognitive and neuroprotective compounds, longevity and anti-aging research peptides, antimicrobial peptides, and cosmetic research compounds.
Their growth hormone secretagogue category included ipamorelin, CJC-1295 (both DAC and no-DAC variants), sermorelin, hexarelin, GHRP-2, and GHRP-6. Metabolic research peptides included GLP-1 receptor agonists, tirzepatide, semaglutide, and related compounds. Tissue repair research compounds included BPC-157, TB-500, and related healing factors. Longevity research peptides included epitalon, GHK-Cu, and NAD+ precursors. Cognitive research compounds included selank and semax variants.
Black Series Lab covers many of these same research categories with a curated catalog focused on quality and documentation integrity. Researchers who previously sourced from Peptide Sciences will find equivalents for the most cited compounds including BPC-157, TB-500, GHK-Cu, Ipamorelin, CJC-1295, Epitalon, and MOTS-c. The full catalog is available at Browse all compounds.
Is Peptide Sciences coming back
There is no indication that Peptide Sciences plans to resume operations. The company's domain remains active but serves only a static shutdown message with no timeline for reopening, no contact information for future updates, and no indication that the closure is temporary.
Given the regulatory environment that prompted the closure — ongoing FDA enforcement actions, proposed legislation expanding agency authority, and the resolution of drug shortage loopholes that previously provided legal cover for certain compound categories — the conditions that would need to change for Peptide Sciences to reopen do not appear imminent.
Researchers should plan for permanent alternatives rather than waiting for a reopening that may never materialize. This means qualifying new suppliers now, validating compound quality through independent testing, and establishing backup supply relationships to prevent future single-point-of-failure disruptions.
The broader lesson from the Peptide Sciences closure extends beyond any single vendor. Research supply chains built around a single source — regardless of how established that source may appear — carry inherent risk. The fact that a company generating $7.4 million per month in revenue could disappear overnight with no warning illustrates the fragility of vendor relationships in an industry undergoing rapid regulatory transformation. Researchers should maintain their own records of COAs, batch numbers, and analytical data from every order, independent of any single vendor's systems.
All compounds referenced in this article are research chemicals intended for laboratory and scientific research purposes only. Black Series Lab does not sell products intended for human consumption. Researchers are responsible for ensuring compliance with all applicable local, state, and federal regulations governing the purchase and use of research materials.